Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Telix Pharmaceuticals Limited clinical trials
The registry lists 31 studies whose lead sponsor is Telix Pharmaceuticals Limited or one of 3 companies grouped under it. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Keep track of what changes. Save the Telix Pharmaceuticals Limited studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Telix Pharmaceuticals Limited.
- Telix Pharmaceuticals (Innovations) Pty Limited21 studies →Subsidiary
Something wrong?
- Lightpoint Medical Limited7 studies →Acquired — became part of Telix Pharmaceuticals Limited, Nov 1, 2023 · source ↗
Something wrong?
- Telix Pharmaceuticals (Innovations) Pty Ltd3 studies →Subsidiary
Something wrong?
Focus areas
Conditions Telix Pharmaceuticals Limited leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 31 of 31.
- Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCCNot yet recruitingNCT07870746Phase 2
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-olaratumab Dosimetry in Participants With PDGFR Alpha Positive Solid Tumours and Soft Tissue SarcomaRecruitingNCT06537596Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Ltd
- Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent GlioblastomaRecruitingNCT07100730Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)RecruitingNCT06520345Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone PainRecruitingNCT07197645Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCCRecruitingNCT07197580Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP StudyRecruitingNCT06750419Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsRecruitingNCT05847348Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid TumorsRecruitingNCT05868174Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- PSMA PET Combined With MRI for the Detection of PCaActive, not recruitingNCT07052214Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)Active, not recruitingNCT05450744Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-DFO-girentuximab Expanded Access Program (EAP)No longer availableNCT06090331
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 18F-Floretyrosine Expanded Access ProgramNo longer availableNCT06743100
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- [18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related ChangesCompletedNCT07238322
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care OnlyTerminatedNCT04876651Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Ltd
- Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging EvaluationsTerminatedNCT06655064
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsTerminatedNCT05563272Phase 2
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Ltd
- External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)CompletedNCT05146973Phase 2
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON StudyCompletedNCT03849118Phase 3
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)CompletedNCT04726033Early Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry StudyCompletedNCT04786847Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell CarcinomaCompletedNCT05861778Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- 131I-IPA and Concurrent XRT in Recurrent GBMCompletedNCT03849105Phase 1/2
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCCCompletedNCT04496089Phase 1
Sponsor listed in the registry: Telix Pharmaceuticals (Innovations) Pty Limited
- Evaluation of the SENSEI® Laparoscopic Tethered Gamma Probe for 99mTc-nanocolloid Sentinel Lymph Node Biopsy in Prostate CancerStatus unknownNCT04632251Not applicable
Sponsor listed in the registry: Lightpoint Medical Limited · First submitted before Lightpoint Medical Limited became part of Telix Pharmaceuticals Limited
- The LightPath® and 68Ga-RM2 in Breast Cancer StudyStatus unknownNCT03731026Phase 3
Sponsor listed in the registry: Lightpoint Medical Limited · First submitted before Lightpoint Medical Limited became part of Telix Pharmaceuticals Limited
- The LightPath® Breast Cancer StudyStatus unknownNCT02666079Not applicable
Sponsor listed in the registry: Lightpoint Medical Limited · First submitted before Lightpoint Medical Limited became part of Telix Pharmaceuticals Limited
- Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour SurgeryWithdrawnNCT02446379
Sponsor listed in the registry: Lightpoint Medical Limited · First submitted before Lightpoint Medical Limited became part of Telix Pharmaceuticals Limited
- The Breast Surgery EnLight and LightPath Imaging System StudyStatus unknownNCT02151071Phase 1/2
Sponsor listed in the registry: Lightpoint Medical Limited · First submitted before Lightpoint Medical Limited became part of Telix Pharmaceuticals Limited
- LightPathTM Imaging System for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical SpecimensCompletedNCT02037269
Sponsor listed in the registry: Lightpoint Medical Limited · First submitted before Lightpoint Medical Limited became part of Telix Pharmaceuticals Limited
- PRIME - PRostate Imaging for Margin EvaluationCompletedNCT02151097
Sponsor listed in the registry: Lightpoint Medical Limited · First submitted before Lightpoint Medical Limited became part of Telix Pharmaceuticals Limited